Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD) will release its first-quarter 2021 financial results on July 1, 2021. A conference call will occur at 8:30 a.m. EDT to discuss these results and recent corporate developments. Stakeholders can access the call via phone or live audio webcast. Additionally, the company's innovative ROCK® platform aims to enhance cancer treatment through the innate immune system, positioning Affimed as a leader in immuno-oncology with a clinical-stage ICE®. Further information is available on their website.

Positive

• The ROCK® platform supports a broad pipeline for cancer therapies.
• Affimed is the first company with a clinical-stage ICE®.

Negative

• None.

HEIDELBERG, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release first quarter 2021 results on Thursday, July 1, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

The conference call will be available via phone and webcast. To access the first quarter results call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 4485380 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the “Investors” section of company’s website at https://www.affimed.com/investors/webcasts_cp/. A replay of the call will be archived on the Affimed website for 30 days after the call.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When will Affimed release its Q1 2021 results?

Affimed will release its first-quarter 2021 financial results on July 1, 2021.

What time is the Affimed conference call for Q1 2021 results?

The conference call will be held at 8:30 a.m. EDT on July 1, 2021.

How can I access Affimed's Q1 2021 conference call?

You can access the call via phone at +1 (409) 220-9054 for U.S. callers or +44 (0) 8000 323836 for international callers.

What is the significance of Affimed's ROCK® platform?

The ROCK® platform enables a tumor-targeted approach to harness the innate immune system for treating various cancers.

Where can I find more information about Affimed?

More information can be found on Affimed's website at www.affimed.com.